Cell Therapeutics to co-develop tosedostat, a potential non-cytotoxic oral therapy for acute myeloid leukemia, with U.K. biotech Chroma Therapeutics.
Join thousands of industry professionals who rely on Pink Sheet for daily insights
Already a subscriber?
Pink Sheet reporter and editors discuss CBER Director Vinay Prasad’s expectation to stay out of routine application decisions, despite the agency’s top-down leadership approach, and the extent of proposed FDA budget cuts.
The EU product information for Novo Nordisk’s semaglutide medicines is to be updated to include non-arteritic anterior ischemic optic neuropathy as a side effect with a frequency of “very rare.”
The Pink Sheet explores how regulatory approvals for Leqembi differ around the world, and looks at what is coming next.
